We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Uses Infrared Light to Detect Brain Cancer

By LabMedica International staff writers
Posted on 23 Oct 2023
Print article
Image: The Dxcover platform detects the presence or absence of disease in minutes (Photo courtesy of Dxcover)
Image: The Dxcover platform detects the presence or absence of disease in minutes (Photo courtesy of Dxcover)

Every year, more than 86,000 new brain cancer cases are identified globally, and these tend to be more costly to treat initially than other types of cancer. The average life span is cut short by about 20 years due to brain tumors. An early diagnosis greatly improves the chances of successful treatment and a better quality of life. However, in primary healthcare settings, diagnosing brain cancer is extremely challenging. Most patients exhibit symptoms that are vague and usually not immediately life-threatening, making it tough to determine who needs further, expensive testing like brain scans. Now, an innovative liquid biopsy using spectroscopy offers a quick, affordable, and accurate method for doctors to test for brain cancer, cutting down on delays for additional tests and treatments.

Dxcover’s (Glasgow, UK) brain cancer blood test utilizes infrared light on blood samples to assess whether a patient is likely to have cancer. This approach is grounded in research showing that the interplay between the light and molecules in the blood can generate a biological signal. This signal is then analyzed using machine learning to ascertain if the patient has cancer. In the test, a tiny amount of blood serum is dried onto a specialized Dxcover Slide and then examined using infrared light. All critical data, including how the body is responding to potential illness, is recorded. An AI algorithm quickly processes this information, even offering insight into the type and intensity of the tumor, helping healthcare providers to prioritize treatment plans more effectively.

In a 2021 study, the test successfully identified glioblastoma, a particularly aggressive form of brain tumor, with 91% sensitivity and 80% specificity. Overall, the test had an 81% sensitivity rate for all kinds of brain tumors. Dxcover is continually fine-tuning the test's accuracy for various applications. The highly sensitive nature of the test enables doctors to efficiently triage patients and rule out cancer as a cause for their symptoms. Dxcover plans to introduce its blood test in Europe to aid in the assessment of patients showing symptoms of cancer. The company expects to finalize clinical trials and secure a CE Mark for the test’s commercial release in the European Union by 2025. Meanwhile, in the United States, the test's high specificity could prove instrumental in detecting brain cancer at an earlier stage, according to the company.

Related Links:
Dxcover

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.